Limits...
A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer.

Bai L, Wang F, Zhang DS, Li C, Jin Y, Wang DS, Chen DL, Qiu MZ, Luo HY, Wang ZQ, Li YH, Wang FH, Xu RH - Sci Rep (2015)

Bottom Line: Patients with lower pretreatment levels of hepatocyte growth factor (HGF) or VEGF-A(121) gain much more benefit from bevacizumab treatment as measured by progression-free survival (PFS) and overall survival (OS), while angiopoietin-like 4 (ANGPTL4) levels negatively correlated with PFS and response rate following bevacizumab (all adjusted interaction P < 0.05).Signature-negative patients showed impaired survival following bevacizumab treatment (PFS, 7.3 vs 7.0 months; hazard ratio [HR] 1.03; OS, 29.9 vs 21.1 months, HR 1.33) compared with signature-positive patients (PFS, 6.5 vs 11.9 months, HR 0.52; OS, 28.0 vs 55.3 months, HR 0.67).These promising results warrant further prospective studies.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China.

ABSTRACT
This study intends to identify biomarkers that could refine the selection of patients with metastatic colorectal cancer (mCRC) for bevacizumab treatment. Pretreatment 36 plasma cytokines and angiogenic factors (CAFs) were first measured by protein microarray analysis in patients who received first-line bevacizumab-containing therapies (discovery cohort, n = 64), and further evaluated by enzyme-linked immunosorbent assay in patients treated on regimens with or without bevacizumab (validation cohort, n = 186). Factor levels were correlated with clinical outcomes, predictive values were assessed using a treatment by marker interaction term in the Cox model. Patients with lower pretreatment levels of hepatocyte growth factor (HGF) or VEGF-A(121) gain much more benefit from bevacizumab treatment as measured by progression-free survival (PFS) and overall survival (OS), while angiopoietin-like 4 (ANGPTL4) levels negatively correlated with PFS and response rate following bevacizumab (all adjusted interaction P < 0.05). A baseline CAF signature combining these three markers has greater predictive ability than individual markers. Signature-negative patients showed impaired survival following bevacizumab treatment (PFS, 7.3 vs 7.0 months; hazard ratio [HR] 1.03; OS, 29.9 vs 21.1 months, HR 1.33) compared with signature-positive patients (PFS, 6.5 vs 11.9 months, HR 0.52; OS, 28.0 vs 55.3 months, HR 0.67). These promising results warrant further prospective studies.

No MeSH data available.


Related in: MedlinePlus

A typical individual slice of protein microarray, using a panel of 36 cytokines from RayBio® Human Angiogesis Antibody Array 2, the images were captured using a GenePix® 4000A scanner, a total of 8 slices (2 slices for each patient) were processed to generate data for 64 patients.POS1, positive control 1; POS2, positive control 2; NEG, negative control; ENA-78/CXCL5, neutrophil-activating peptide 78/chemokine (C-X-C motif) ligand 5.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664961&req=5

f2: A typical individual slice of protein microarray, using a panel of 36 cytokines from RayBio® Human Angiogesis Antibody Array 2, the images were captured using a GenePix® 4000A scanner, a total of 8 slices (2 slices for each patient) were processed to generate data for 64 patients.POS1, positive control 1; POS2, positive control 2; NEG, negative control; ENA-78/CXCL5, neutrophil-activating peptide 78/chemokine (C-X-C motif) ligand 5.

Mentions: Figure 2 represents one of the microarray slices. The MDVs of bFGF, HB-EGF and TPO were below detection threshold in more than 20% patients and was not further analyzed for clinical parameter relevance.


A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer.

Bai L, Wang F, Zhang DS, Li C, Jin Y, Wang DS, Chen DL, Qiu MZ, Luo HY, Wang ZQ, Li YH, Wang FH, Xu RH - Sci Rep (2015)

A typical individual slice of protein microarray, using a panel of 36 cytokines from RayBio® Human Angiogesis Antibody Array 2, the images were captured using a GenePix® 4000A scanner, a total of 8 slices (2 slices for each patient) were processed to generate data for 64 patients.POS1, positive control 1; POS2, positive control 2; NEG, negative control; ENA-78/CXCL5, neutrophil-activating peptide 78/chemokine (C-X-C motif) ligand 5.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664961&req=5

f2: A typical individual slice of protein microarray, using a panel of 36 cytokines from RayBio® Human Angiogesis Antibody Array 2, the images were captured using a GenePix® 4000A scanner, a total of 8 slices (2 slices for each patient) were processed to generate data for 64 patients.POS1, positive control 1; POS2, positive control 2; NEG, negative control; ENA-78/CXCL5, neutrophil-activating peptide 78/chemokine (C-X-C motif) ligand 5.
Mentions: Figure 2 represents one of the microarray slices. The MDVs of bFGF, HB-EGF and TPO were below detection threshold in more than 20% patients and was not further analyzed for clinical parameter relevance.

Bottom Line: Patients with lower pretreatment levels of hepatocyte growth factor (HGF) or VEGF-A(121) gain much more benefit from bevacizumab treatment as measured by progression-free survival (PFS) and overall survival (OS), while angiopoietin-like 4 (ANGPTL4) levels negatively correlated with PFS and response rate following bevacizumab (all adjusted interaction P < 0.05).Signature-negative patients showed impaired survival following bevacizumab treatment (PFS, 7.3 vs 7.0 months; hazard ratio [HR] 1.03; OS, 29.9 vs 21.1 months, HR 1.33) compared with signature-positive patients (PFS, 6.5 vs 11.9 months, HR 0.52; OS, 28.0 vs 55.3 months, HR 0.67).These promising results warrant further prospective studies.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China.

ABSTRACT
This study intends to identify biomarkers that could refine the selection of patients with metastatic colorectal cancer (mCRC) for bevacizumab treatment. Pretreatment 36 plasma cytokines and angiogenic factors (CAFs) were first measured by protein microarray analysis in patients who received first-line bevacizumab-containing therapies (discovery cohort, n = 64), and further evaluated by enzyme-linked immunosorbent assay in patients treated on regimens with or without bevacizumab (validation cohort, n = 186). Factor levels were correlated with clinical outcomes, predictive values were assessed using a treatment by marker interaction term in the Cox model. Patients with lower pretreatment levels of hepatocyte growth factor (HGF) or VEGF-A(121) gain much more benefit from bevacizumab treatment as measured by progression-free survival (PFS) and overall survival (OS), while angiopoietin-like 4 (ANGPTL4) levels negatively correlated with PFS and response rate following bevacizumab (all adjusted interaction P < 0.05). A baseline CAF signature combining these three markers has greater predictive ability than individual markers. Signature-negative patients showed impaired survival following bevacizumab treatment (PFS, 7.3 vs 7.0 months; hazard ratio [HR] 1.03; OS, 29.9 vs 21.1 months, HR 1.33) compared with signature-positive patients (PFS, 6.5 vs 11.9 months, HR 0.52; OS, 28.0 vs 55.3 months, HR 0.67). These promising results warrant further prospective studies.

No MeSH data available.


Related in: MedlinePlus